Description

Hologic Goes Global: Can International Expansion Offset China and Africa Headwinds?

Hologic’s third quarter fiscal 2025 results provide a complex picture of the company’s current financial health and future outlook. Positives include solid performance in several business areas, while challenges continue to affect overall growth. Revenue for the third quarter reached $1.024 billion, slightly increasing by 0.4% year-over-year, surpassing the high end of guidance by $14 million. This represents a rebound from previous challenges and signifies momentum in operations. Non-GAAP earnings per share stood at $1.08, a 1.9% increase from the previous year. Hologic maintained a robust operating margin above 30%, showcasing efficient cost management and mitigating impacts from global tariffs. The Diagnostics division experienced growth, with revenue increasing to $448.9 million, representing a 0.9% overall increase and 2.9% growth when excluding COVID-related sales. The business faced headwinds from geopolitical factors, particularly funding cuts in Africa and challenges in China. Molecular diagnostics emerged strong, particularly in the U.S. with a 7.